Common Immune-Mediated Disease 4) Immune-Mediated Thrombocytopenia

1. Classification/Etiology

  • ITP = idiopathic thrombocytopenic purpura
    • IMT = Immune-mediated thrombocytopenia ๋ผ๊ณ ๋„ ํ•จ.
    • ํ˜ˆ์†ŒํŒ์ด ๊ฐ์†Œํ•˜์—ฌ ๋ฉ์ด ์ž˜ ๋“ฆ.
  • ํ•ญ์ฒด๋งค๊ฐœ๋กœ ๊ฐ€์†ํ™”๋œ ํ˜ˆ์†ŒํŒ์˜ ๊ฐ์†Œ๊ฐ€ ์œ ๋ฐœํ•œ thrombocytopenia (accelerated destruction of platelets)
  • ๊ฐœ์—์„œ ์‹ฌ๊ฐํ•œ thrombocytopenia? ITP ๋•Œ๋ฌธ์ผ ๋•Œ๊ฐ€ ๊ฐ€์žฅ ํ”ํ•˜๋‹ค.

Primary autoimmune thrombocytopenia

  • Antibodies - platelet antigens์˜ ๊ฒฐํ•ฉ
    • Platelet membrane glycoproteins โ…กb/โ…ขa + Others
  • ์ฃผ๋กœ ๋ฉด์—ญ ์กฐ์ ˆ์˜ ๊ฒฐํ•จ์œผ๋กœ ์ธํ•ด ๋ฐœ์ƒํ•œ๋‹ค.
  • ๊ฐœ์—์„œ๋Š” ํ”ํ•œ ์›์ธ์ด๋‚˜, ๊ณ ์–‘์ด์—์„œ๋Š” ๋“œ๋ฌผ๋‹ค.
  • stress, ํ™˜๊ฒฝ ์˜จ๋„์˜ ๋ณ€ํ™”, ํ˜ธ๋ฅด๋ชฌ ๋ณ€ํ™”, ๋ฐฑ์‹ ์˜ ์ด๋ฌผ, ์ˆ˜์ˆ  ๋“ฑ ํ™˜๊ฒฝ์  ์š”์ธ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค.

Secondary ITP

  • ๊ธฐ์ €์งˆํ™˜(inflammatory or neoplastic disease)์— ์˜ํ•ด โ†’ ํ•ญ์ฒด ๋งค๊ฐœ ํ˜ˆ์†ŒํŒ ํŒŒ๊ดด๊ฐ€ ๋‚˜ํƒ€๋‚จ.
  • Evans syndrome : ITP + IMHA
  • SLE
CauseDogsCats
NeoplasiaLymphoma
Hemangiosarcoma
Leukemia
Malignant histiocytosis
Histiocytic sarcoma
Unclassified carcinoma/sarcoma
โ€ฆ
Lymphoma
Hemangiosarcoma
Leukemia
โ€ฆ
InfectionEhrlichia canis
Anaplasma phagocytophilum
Anaplasma platys
Rocky Mountain spotted fever
Babesiosis
Leishmaniasis
Leptospirosis
Distemper virus infection
โ€ฆ
Feline leukemia virus
Feline immunodeficiency virus
Feline infectious peritonitis virus
Feline panleukopenia cirus
Toxoplasmosis
Exposure to drugs,
vaccines, toxins
ํ•ญ์ƒ์ œ (Trimethoprim, sulfadiazine ๋“ฑ)
Phenobarbital
Primidone
Griseofulvin
Methimazole
Albendazole
Chloramphenicol
DICNeoplasia
Hepatic disease
Infection
Pancreatitis
Neoplasia
Hepatic disease
Infection
Pancreatitis
Inherited
macrothrombocytopenia
Cavalier King Charles Spaniel
Norfolk Terrier
Beagle

๋…ผ๋ฌธ ์†Œ๊ฐœ) ๋ฐฑ์‹  ์ ‘์ข…๊ณผ ITP ๋ฐœ๋ณ‘์€ ๊ด€๋ จ ์žˆ์„๊นŒ?

  • ITP ๊ฑธ๋ฆฐ 48๋งˆ๋ฆฌ ์ค‘ ๋ฐฑ์‹  ๋งž์€ ๊ฑด 8% ์ •๋„,,
  • ๋ณ„๋กœ ์ƒ๊ด€๊ด€๊ณ„๊ฐ€ ์—†๋Š” ๊ฒƒ ๊ฐ™๋‹ค?

2. Clinical Features

  • ํ‰๊ท  6๋…„๋ น, but ๊ด‘๋ฒ”์œ„ํ•˜๊ฒŒ ๋ฐœ๋ณ‘ (8๊ฐœ์›”-15์‚ด)
  • Female >> males (์•”์ปท์—์„œ 2๋ฐฐ ์ •๋„ ๋” ๋งŽ์ด ๋ฐœ๋ณ‘)
  • ์–ด๋–ค ํ’ˆ์ข…์—์„œ๋„ ๊ฑธ๋ฆด ์ˆ˜ ์žˆ์œผ๋‚˜,
    • Cocker Spaniel, Poodles (all), German Shepherd, Old English Sheepdog

Common findings

  • ์ดˆ๊ธฐ : ํ˜ˆ์†ŒํŒ์ด ์—†์–ด ์ž๋ฐ˜์ด ์ƒ๊น€ (ํ”ผ๋ถ€์™€ ์ ๋ง‰์— Petechial & ecchymotic hemorrhages)
  • ์ง€ํ˜ˆ์ด ์ž˜ ์•ˆ ๋จ โ†’ Epistaxis, Hematochezia(ํ˜ˆ๋ณ€), Hematemesis(ํ˜ˆํ† ), Easy bruising(๋ฉ์ด ์ž˜ ๋“ฆ)
  • Lethargy, Weakness, Anorexia (์ฆ์ƒ์ด ์ง€์†๋˜๋ฉด ๊ธฐ๋ ฅ ๋น ์ง)

์‹ ์ฒด๊ฒ€์‚ฌ ์ƒ Additional findings -์ˆ˜์˜์‚ฌ์˜ ์ฃผ์˜

  • Evidence of melena or hematochezia (์ž ํ˜ˆ ์ฃผ์˜)
  • Hematuria (๋ณดํ˜ธ์ž๊ฐ€ ๋†“์น  ์ˆ˜ ์žˆ๋Š” ๋ฏธ์„ธํ•œ ํ˜ˆ๋‡จ ์ฃผ์˜)
  • Hyphema(์ „๋ฐฉ์ถœํ˜ˆ), Retinal hemorrhage โ†’ ์•ˆ๊ตฌ ์ชฝ ์ถœํ˜ˆ๋กœ blindness
  • Pale MMC
  • ๋‡Œํ˜ˆ๊ด€ ์ถœํ˜ˆ๋กœ ์ธํ•ด Neurologic signs (+๋ˆˆ ๊ด€๋ จ ์ฆ์ƒ)
  • ํ˜ˆ์†ŒํŒ ๊ฐ์†Œ๋Š” rapidํ•˜๊ฒŒ ๋ฐœ์ƒํ•˜๋‚˜, ์ง„ํ–‰ ์†๋„๋Š” ๋А๋ฆผ. ๋นˆํ˜ˆ๊ณผ ๊ฐ™์ด ์ƒ๋ช…์„ ์œ„ํ˜‘ํ•˜๋Š” ์†Œ๊ฒฌ์€ ์ฒœ์ฒœํžˆ ๋‚˜ํƒ€๋‚จ(life-threatening hemorrhage is rare)
  • Cf) ITP ๊ฑธ๋ฆฐ ๊ฐœ์˜ ํ˜ˆ์ฒญ๊ณผ platelet๊ณผ incubation โ†’ ํ˜ˆ์†ŒํŒ์ด ๊ธฐ๋Šฅ์„ ์žƒ์Œ. (์‘์ง‘ ๋ถˆ๊ฐ€)
    โ‡’ ITP ๊ฑธ๋ฆฐ ๊ฐœ์˜ ํ˜ˆ์ฒญ์— ๋ฌด์–ธ๊ฐ€ ํ˜ˆ์†ŒํŒ์„ ๋ฌด๋ ฅํ™”์‹œํ‚ค๋Š” ํ•ญ์ฒด๋‚˜ ๋‹ค๋ฅธ factor๊ฐ€ ์กด์žฌํ•˜๋Š” ๊ฒƒ ๊ฐ™๋‹ค
  • ์˜ˆ์™ธ์ ์œผ๋กœ, Evans syndrome์˜ ๊ฒฝ์šฐ ํ˜ˆ์†ŒํŒ+์ ํ˜ˆ๊ตฌ๊ฐ€ ํ•œ ๋ฒˆ์— ๊ฐ์†Œํ•˜๊ธฐ ๋•Œ๋ฌธ์— ์‹ฌ๊ฐํ•  ์ˆ˜ ์žˆ์Œ.
  • ํ˜ˆ์†ŒํŒ์„ ์ถฉ๋ถ„ํžˆ ๋„ฃ์–ด์คฌ๋Š”๋ฐ๋„ ๋–จ์–ด์ง„๋‹ค๋ฉด, ๋‹ค๋ฅธ ์›์ธ์ด ์žˆ์„ ์ˆ˜๋„ ์žˆ๋‹ค
  • ํ’ˆ์ข… ์†Œ์ธ - ์ผ๋ถ€ ์ข…์—์„œ ์„ ์ฒœ์ ์œผ๋กœ ํ˜ˆ์†ŒํŒ์ด ์ ๊ฑฐ๋‚˜, ํฐ ํ˜ˆ์†ŒํŒ์„ ๊ฐ€์ง„ ๊ฒฝ์šฐ ์žˆ์Œ
    • Greyhound : ํ˜ˆ์†ŒํŒ ์ˆ˜์น˜๊ฐ€ ๋ณดํ†ต๋ณด๋‹ค ๋‚ฎ์€ ํŽธ. (but ์ถœํ˜ˆ ์œ„ํ—˜์ด ๋†’์•„์ง€๋Š” ๊ฑด X)
      • ์ฐธ๊ณ ) ์šฐ๋ฆฌ๋‚˜๋ผ์—์„œ ๋ณด์ด๋Š” ๊ทธ๋ ˆ์ดํ•˜์šด๋“œ๋Š” ๋ณดํ†ต Italian์ด๋ผ ํ•ด๋‹น X, Hgb ๋†’๊ณ  Fe๋„ ๋†’์Œ.
    • Cavalier King Charles Spaniels, Norfolk Terrier : Macrothrombocytopenia
      • ฮฒ1-tubulin mutation์œผ๋กœ ์ธํ•ด โ†’ ํ˜ˆ์†ŒํŒ ์ˆ˜ ๊ฐ์†Œ(<30,000/ฮผL), MPV ์ฆ๊ฐ€
      • ์ถœํ˜ˆ ์†Œ๊ฒฌ ์—†์Œ, ์น˜๋ฃŒ ํ•„์š” ์—†์Œ (๊ทธ๋ƒฅ ํ’ˆ์ข… ์†Œ์ธ)

3. Diagnosis

  • ITP๋Š” ๋‹ค๋ฅธ ์งˆ๋ณ‘๊ณผ ๊ฐ™์ด ๋ฐœ์ƒํ•  ๋•Œ๊ฐ€ ๋งŽ์Œ.
  • Primary ITP์˜ ์ง„๋‹จ์€ ๋‹ค๋ฅธ thrombocytpenia ์›์ธ์„ rule-outํ•จ์œผ๋กœ์จ ๊ฐ€๋Šฅํ•จ.

โœ… ํ˜ˆ์•ก ๊ฒ€์‚ฌ

  • Primary ITP โ†’ ํ˜ˆ์†ŒํŒ๊ฐ์†Œ๊ฐ€ ์‹ฌ๊ฐํ•จ. (<50,000 platelets/ฮผL)

    • Platelet counts๋Š” primary ITP < secondary ITP < ๋น„๋ฉด์—ญ์›์„ฑ thrombocytopenia(์ถœํ˜ˆ ๋“ฑ)
  • ํ˜ˆ์•ก ๋„๋ง์—์„œ

    • Microthrombocytosis (Platelet fragments)
      • ๋ฉด์—ญ ์†์ƒ(immune injury) ํ˜น์€ ๋Œ€ํ˜• ํ˜ˆ์†ŒํŒ์ด ๋จผ์ € ์ œ๊ฑฐ๋˜์–ด์„œ ๋‚˜ํƒ€๋‚œ๋‹ค.
      • insensitive (๋ฐœ๊ฒฌ๋˜์ง€ ์•Š๋Š”๋‹ค๊ณ  ํ•ด์„œ ์•„๋‹Œ ๊ฑด ์•„๋‹ˆ์ง€๋งŒ), but specific (๋ฐœ๊ฒฌ๋˜๋ฉด ITP์ผ ๊ฐ€๋Šฅ์„ฑ์ด ๋” ๋†’์Œ)
    • Large platelets
      • ๊ณจ์ˆ˜์—์„œ ํ˜ˆ์†ŒํŒ ์ƒ์„ฑ ๊ธฐ๋Šฅ์€ ์ •์ƒ์ด๋ผ๋Š” ์ง€ํ‘œ์ผ ์ˆ˜๋„ ์žˆ๋Š”๋ฐ,
      • ๊ณจ์ˆ˜์˜ ์†์ƒ์œผ๋กœ ์‹ค์ˆ˜๋กœ ํฐ ํ˜ˆ์†ŒํŒ์„ ๋งŒ๋“ค ์ˆ˜ ์žˆ์Œ.
      • ๋”ฐ๋ผ์„œ ์žฌ์ƒ๋ฐ˜์‘์ผ ์ˆ˜๋„ ์žˆ์ง€๋งŒ, ์•„๋‹ ์ˆ˜๋„ ์žˆ์Œ.
  • MPV (Mean Platelet Volume) : large platelet์ด ๋งŽ์œผ๋ฉด MPV โ†‘ , microthrombocytes๊ฐ€ ๋งŽ์œผ๋ฉด MPV โ†“

    • thrombocytopenia๊ฐ€ ์žˆ์„ ๋•Œ, primary ITP๋Š” MPV๊ฐ€ ๋‚ฎ์€ ํŽธ์ด๋ผ๋Š” ๊ต์žฌ์˜ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ.
    • MPV๊ฐ€ ๋” ํด ์ˆ˜๋„ ์žˆ๋‹ค๋Š” ์ตœ๊ทผ ์—ฐ๊ตฌ ๊ฒฐ๊ณผ.
  • Thrombocytopenia๋Š” ์žˆ๋Š”๋ฐ ๊ทธ๋กœ ์ธํ•œ ์ฆ์ƒ(์ž๋ฐ˜, ์‰ฝ๊ฒŒ ๋ฉ๋“ฆ, ๋นˆํ˜ˆ ๋“ฑ)์ด ์—†๋‹ค๋ฉด

    • ์ง„์งœ ํ˜ˆ์†ŒํŒ ๊ฐ์†Œ์ธ์ง€ ์ƒ๊ฐํ•ด๋ด๋ผ (ํ’ˆ์ข… ์†Œ์ธ์€ ์—†๋Š”์ง€) : Breed-related thrombocytopenia
    • ํ˜ˆ์†ŒํŒ์ด ๋งŽ์ด ๋ชฐ๋ ค์žˆ์œผ๋ฉด ์ •ํ™•ํžˆ ์ธก์ • X (10๋งŒ ๊ฐœ ์ดํ•˜๋ฉด ๊ผญ ๋„๋ง ํ™•์ธํ•ด๋ณด๊ธฐ) : Platelet clumping, spurious thrombocytopenia
    • ๊ธฐ๊ณ„์— ๋”ฐ๋ผ ๋‚ฎ๊ฒŒ ๋‚˜์˜ค๋Š” ์ธก์ • ๊ธฐ๊ณ„๋„ ์žˆ์Œ (์ค‘๊ตญ์‚ฐ) : Technical problems

โœ… ๊ณจ์ˆ˜ ๊ฒ€์‚ฌ

  • ํ˜ˆ์†ŒํŒ ์ƒ์‚ฐ ๊ฐ์†Œ / ํ˜ˆ์†ŒํŒ ์†Œ๋ชจ ์ฆ๊ฐ€ / ํ˜ˆ์†ŒํŒ ํŒŒ๊ดด ์ค‘ ๋ฌด์—‡์— ํ•ด๋‹นํ•˜๋Š”์ง€ ๊ฐ๋ณ„ํ•˜๊ธฐ์— ๊ฐ€์žฅ ์ข‹์€ ๋ฐฉ๋ฒ•.
  • ๊ถŒ์žฅ๋˜๋Š” ์ƒํ™ฉ : Severe thrombocytopenia (<20,000/ฮผL) / or ๋‹ค๋ฅธ hematologic abnormalities (cytopenias)์˜ ์ฆ๊ฑฐ๊ฐ€ ์žˆ์„ ๋•Œ
    โ‡’ DDx : Myelophthisis, neoplasia, megakaryotic aplasia, aplastic anemia
    • Megakaryocytic aplasia๋กœ ์ธํ•ด ์‹ฌ๊ฐํ•œ ํ˜ˆ์†ŒํŒ ๊ฐ์†Œ๋ฅผ ๋‚˜ํƒ€๋‚ด๋Š” ๊ฒฝ์šฐ๋Š” ๋“œ๋ฌผ๋‹ค.
    • primary์ผ ์ˆ˜๋„ ์žˆ์ง€๋งŒ, Ehrlichia canis, Borrelia burgdorferi(๋ผ์ž„๋ณ‘) ๋“ฑ ๊ฐ์—ผ์— ๋Œ€ํ•ด secondaryํ•  ์ˆ˜๋„ ์žˆ๋‹ค.
    • ITP(ํŠน๋ฐœ์„ฑ)๊ณผ ๋น„์Šทํ•˜์ง€๋งŒ, ๋” ์‹ฌ๊ฐํ•˜๊ณ  ์•ฝ๋ฌผ ๋ฐ˜์‘์ด ๋–จ์–ด์ ธ ์˜ˆํ›„๊ฐ€ ๋ถˆ๋Ÿ‰ํ•˜๋‹ค.
    • ์ถœํ˜ˆ ์šฐ๋ ค๋กœ ์‹œ๋„ํ•˜์ง€ ์•Š๋Š” ๊ฑด X - ์‹ฌ๊ฐํ•œ ํ˜ˆ์†ŒํŒ๊ฐ์†Œ์ฆ์—์„œ๋„ ๊ตญ์†Œ์ ์œผ๋กœ ์ž˜ ์ง€ํ˜ˆํ•ด์„œ ์•ˆ์ „ํ•˜๊ฒŒ ์‹œํ–‰๋  ์ˆ˜ ์žˆ๋‹ค.
  • Megakaryocytic hyperplasia > Megakaryocytes ์ •์ƒ >>> Megakaryocytes ๊ฐ์†Œ; ์˜ˆํ›„ ์•ˆ ์ข‹์Œ

โœ… Platelet-bound antibody

  • ์›๋‚ด ๊ฒ€์‚ฌ๋Š” ์–ด๋ ต๊ณ , ๊ฒ€์‚ฌ ์˜๋ขฐ ํ•„์š”.
  • ์šฐ๋ฆฌ๋‚˜๋ผ์—์„œ๋Š” ๋ถˆ๊ฐ€๋Šฅํ•˜๊ณ , ๋ฏธ๊ตญ์—์„œ๋„ ๊ฐ€๊นŒ์šด ์ง€์—ญ์—์„œ๋งŒ ๊ฐ€๋Šฅํ•œ ๋ฐฉ๋ฒ•.
  • Highly sensitive : ์Œ์„ฑ์ด๋ฉด ITP ์•„๋‹ ๊ฒƒ.
  • ์ด์ „์— ๋ฉด์—ญ์–ต์ œ ์น˜๋ฃŒ๋ฅผ ํ–ˆ์œผ๋ฉด ์Œ์„ฑ ๊ฒฐ๊ณผ๊ฐ€ ๋‚˜์˜ฌ ์ˆ˜ ์žˆ์Œ.
  • ์–‘์„ฑ ๊ฒฐ๊ณผ๊ฐ€ ๋‚˜์™€๋„ primary ITP์— ๋Œ€ํ•ด non-specific - ์†๋ฐœ์„ฑ ์›์ธ์ด ๋”ฐ๋กœ ์žˆ์„ ์ˆ˜ ์žˆ๋‹ค.
    • neoplasia, inflammation, drug reactions, infectious casuse ๋“ฑ

์ง„๋‹จ ์•Œ๊ณ ๋ฆฌ์ฆ˜

  1. History, Physical exmination
  2. MDB (CBC, chemistry, urinalysis) /
    Coagulation status (Platelet, aPTT, PT, FDPs) /
    Imaging (Mass, ์ž๊ถ์ถ•๋†์ฆ)
  3. Infectious disease titers (์ง€๋ฆฌ์  ์š”์ธ ๊ณ ๋ ค) /
    Bone marrow exam (์‹ฌ๊ฐํ•œ ๊ฒฝ์šฐ)
  • ITP์˜ ๋Œ€๋ถ€๋ถ„์€ megakaryocytic hyperplasia
  • ๋“œ๋ฌผ๊ฒŒ ๋‚˜ํƒ€๋‚˜๋Š” megakaryocytic aplasia / hypoplasia โ‡’ ๊ณจ์ˆ˜๊ฒ€์‚ฌ๋กœ๋งŒ ์ง„๋‹จ ๊ฐ€๋Šฅ. (๋ฃจํ‹ดํ•œ ๋ฉด์—ญ์–ต์ œ ์น˜๋ฃŒ์— ๋ฐ˜์‘ํ•˜์ง€ ์•Š์„ ๋•Œ ๋’ค๋Šฆ๊ฒŒ ์‹œํ–‰๋˜๊ธฐ๋„ ํ•จ)

Treatment

  • ๋ฉด์—ญ์–ต์ œ์ œ ์น˜๋ฃŒ๊ฐ€ ํ•ต์‹ฌ.
  • ๊ฐ์—ผ์› ๊ฒ€์‚ฌ์— ์‹œ๊ฐ„์ด ์†Œ์š”๋  ์ˆ˜ ์žˆ์œผ๋‹ˆ, ๊ฒฐ๊ณผ๋ฅผ ๊ธฐ๋‹ค๋ ค๋ณผ ๊ฒƒ / ๊ทธ๋Ÿฌ๋‚˜ ๋ฐฐ์ œ๋˜๊ธฐ ์ „ ์• ๋งคํ•˜๋ฉด doxycycline ๊ทธ๋ƒฅ ๊ฐ™์ด ์ฃผ๊ธฐ๋„ ํ•จ.

1) Corticosteroid

Corticosteroids
PDS2-4mg/kg/day PO
Dexamethasone0.25-0.6mg/kg IV q24h - 1,2๋ฒˆ ์†Œ๋Ÿ‰ ํˆฌ์—ฌ
Vincristine+PDS์น˜๋ฃŒ ์†๋„ ๋น ๋ฆ„, ์น˜๋ฃŒ ๊ธฐ๊ฐ„ ๋‹จ์ถ•
- ์‹ฌ๊ฐํ•œ ITP์—์„œ 0.02mg/kg IV๋กœ ๋ณ‘์šฉ, ๋‹จ์ผ์šฉ๋Ÿ‰ ๋‹จํšŒํˆฌ์•ฝ
hIVIG+PDSPDS ๋‹จ๋…๋ณด๋‹ค ์ข‹์Œ / ๋„ˆ๋ฌด ๋น„์Œˆ.
- Vincristine ๋ณ‘์šฉ๊ณผ ๋น„๊ตํ–ˆ์„ ๋•Œ, ๋‘˜ ๋‹ค platelet ํšŒ๋ณต ์‹œ๊ฐ„์€ ๋น„์Šท.
- ์กฐ๊ธˆ ๋” ์‹ผ vincristine์„ ์„ ํ˜ธ.
  • Platelet count๊ฐ€ ์ •์ƒ ๋ฒ”์œ„๋กœ ๋“ค์–ด์˜ค๋ฉด, ์žฌ๋ฐœ ์œ„ํ—˜์„ ๊ณ ๋ คํ•˜์—ฌ ์ฒœ์ฒœํžˆ tapering.
  • 3-6๊ฐœ์›” ๋™์•ˆ์€ 20-30%/month ์ด์ƒ ๋น ๋ฅด๊ฒŒ ๊ฐ๋Ÿ‰ํ•˜์ง€ ๋ง ๊ฒƒ.
  • low EOD๊นŒ์ง€ ๊ฐ๋Ÿ‰ํ•˜๊ณ , control ์ž˜ ๋˜๋ฉด ์•„์˜ˆ ๋Š๋Š” ๊ฒƒ๋„ ์‹œ๋„ํ•ด๋ณผ ์ˆ˜ ์žˆ๋‹ค.
  • ์น˜๋ฃŒ๋ฐ˜์‘ ๋„ˆ๋ฌด ์—†์œผ๋ฉด ๊ณจ์ˆ˜ ๊ฒ€์‚ฌ๊ฐ€ ํ•„์š”ํ•˜๋‹ค.

2) ์ถ”๊ฐ€ ๋ฉด์—ญ์–ต์ œ์ œ

  • Steroid๋งŒ ํˆฌ์—ฌํ–ˆ๋Š”๋ฐ ์น˜๋ฃŒ ๋ฐ˜์‘์ด ๋–จ์–ด์งˆ ๋•Œ, ๋ถ€์ž‘์šฉ์ด ์‹ฌํ•ด PDS ์šฉ๋Ÿ‰์„ ์ค„์—ฌ์•ผ ํ•˜๋Š”๋ฐ ๊ทธ๋Ÿด ์ˆ˜ ์—†์„ ๋•Œ.
  • Azathioprine, mycophenolate > cyclosporine ์ด์šฉ
    • Cyclosporine์ด ๋” ๋น„์‹ธ์„œ.. PDS+MMF๊ฐ€ ๋” ์„ ํ˜ธ๋จ.
  • ๋‘ ๋ฒˆ์งธ ๋ฉด์—ญ ์–ต์ œ์ œ๋กœ ์ž˜ ์น˜๋ฃŒ๊ฐ€ ๋˜๋ฉด ์Šคํ…Œ๋กœ์ด๋“œ๋ถ€ํ„ฐ ๊ฐ๋Ÿ‰ > ์Šคํ…Œ๋กœ์ด๋“œ ๋‹จ์•ฝ ํ›„ ๋ฉด์—ญ ์–ต์ œ์ œ ๊ฐ๋Ÿ‰์„ ์ฒœ์ฒœํžˆ ์‹œ๋„
  • ๋งŒ์•ฝ ์žฌ๋ฐœ์ด ๋‚˜ํƒ€๋‚˜๋ฉด, PDS (+ ๋‹ค๋ฅธ ๋ฉด์—ญ์–ต์ œ์ œ) ๋ฅผ ํ‰์ƒ ๋จน์–ด์•ผ ํ•  ์ˆ˜๋„ ์žˆ๋‹ค. (์ตœ์†Œ ํ˜ˆ์†ŒํŒ 100,000๊ฐœ๋Š” ์œ ์ง€๋˜๋„๋ก)
  • ํ˜ˆ์†ŒํŒ ์ˆ˜์น˜ ํ™•์ธ : ์•ฝ๋ฌผ ์šฉ๋Ÿ‰ ๋ณ€๊ฒฝ ์ „์ด๋‚˜, ๋ณ€๊ฒฝ 2์ฃผ ๋’ค ๊ผญ ํ™•์ธ.
  • Splenectomy : ์•ฝ๋ฌผ๋กœ ์ž˜ ์น˜๋ฃŒ๋˜์ง€ ์•Š๊ณ  ๋งŒ์„ฑ์ ์œผ๋กœ ์žฌ๋ฐœํ•  ๋•Œ ๊ณ ๋ คํ•ด๋ณผ ์ˆ˜ ์žˆ๋‹ค,.

3) Supportive care

ํ˜ˆ์†ŒํŒ์ด ๋ถ€์กฑํ•ด ์ง€ํ˜ˆ์ด ์•ˆ ๋˜๋Š” ๋ณ‘์ด๋‹ˆ - ์ถœํ˜ˆ, ์ƒ์ฒ˜ ์ตœ์†Œํ™”๊ฐ€ ์ค‘์š”.

  1. ์ƒ์ฒ˜๋ฅผ ๋ฐฉ์ง€ํ•˜๊ธฐ ์œ„ํ•ด ์ผ€์ด์ง€์—์„œ ์ž˜ ์‰ฌ๊ฒŒ ํ•˜๊ณ , ์šด๋™์„ ์ œํ•œํ•œ๋‹ค.
  2. ํ˜ˆ๊ด€์„ ์ฐŒ๋ฅด๋Š” venipuncture๋ฅผ ์ตœ์†Œํ™”ํ•œ๋‹ค. (๋ถˆ์•ˆํ•˜๋‹ค๊ณ  ๋ง‰ ์ฑ„ํ˜ˆํ•˜์ง€ X)
  3. ๊ผญ ํ•„์š”ํ•œ ๊ฒ€์‚ฌ๋งŒ ํ•œ๋‹ค. (ex-์š”์นดํ…Œํ„ฐ ์žฅ์ฐฉ๋งŒ์œผ๋กœ ๊ฐ์—ผ ์ผ์œผํ‚ฌ ์ˆ˜ ์žˆ์Œ, ์š”๊ฒ€์‚ฌ ๋“ฑ ๊ผญ ํ•„์š”ํ•œ ๊ฑฐ ์•„๋‹ˆ๋ฉด ์กฐ์‹ฌ.)
  • ์ ์ ˆํ•œ ์ˆ˜์ค€์˜ ๋ชจ๋‹ˆํ„ฐ๋ง๊ณผ ์ตœ์†Œํ•œ์˜ ์ฑ„ํ˜ˆ ์‚ฌ์ด์—์„œ ๊ท ํ˜•์„ ์ž˜ ๋งž์ถฐ์•ผ.
  • New hemorrhage๋Š” ์—†๋Š”์ง€ ์ฃผ์˜ ๊นŠ๊ฒŒ monitoring ํ•ด์•ผ ํ•œ๋‹ค.
    • Neurologic or ophthalmologic bleeding ๋“ฑ - ์ž…์› ์ „ ์—†์—ˆ๋˜ ํ˜ˆ๋‡จ ์ฆ์ƒ์ด ์ž…์›ํ•˜๋ฉด์„œ ์ƒ๊ฒผ๊ฑฐ๋‚˜, ๋ˆˆ์ด๋‚˜ ๋‡Œํ˜ˆ๊ด€์˜ ์ถœํ˜ˆ์ด ์ƒ๊ธฐ๊ฑฐ๋‚˜.
    • ์ˆ˜์˜์‚ฌ๋Š” ๋ฉ์ด๋‚˜ ํ˜ˆ๋‡จ ๋“ฑ์„ ๋Œ€์ˆ˜๋กญ์ง€ ์•Š๊ฒŒ ์—ฌ๊ธธ ์ˆ˜ ์žˆ์ง€๋งŒ, ๋ณดํ˜ธ์ž ์ž…์žฅ์—์„œ๋Š” ์ดํ•ดํ•˜๊ธฐ ์–ด๋ ค์›€. ์‚ฌ์ „์— ์ƒํ™ฉ์„ ๊ณ ์ง€ํ•˜๊ณ  ์ž˜ ์„ค๋ช…ํ•ด์ฃผ๋Š” ๊ฒƒ์ด ์‹ ๋ขฐ์— ์žˆ์–ด ์ค‘์š”ํ•˜๋‹ค.
Blood transfusion
  • Platelet-rich plasma, platelet concentrate : ์ด์ƒ์ ์ด๋‚˜, ํ˜„์‹ค์ ์œผ๋กœ ์–ด๋ ต๋‹ค. ๊ฐ€๊ณต ์ค‘์— ํŒŒ๊ดด๋˜๊ธฐ๋„ ํ•จ.
  • Fresh whole blood : ๋ณดํ†ต ํ˜„์‹ค์ ์œผ๋กœ ์ „ํ˜ˆ์„ ๋งŽ์ด ์ค€๋‹ค. (์˜คํžˆ๋ ค ํ˜ˆ์†ŒํŒ ๋” ๋งŽ์ด ๋“ค์–ด ์žˆ์„ ์ˆ˜๋„? / ์ฑ„ํ˜ˆํ•˜๊ณ  4โ„ƒ์—์„œ 12h ์•ˆ์— ๋ถ„๋ฆฌ)
    • ํšจ๊ณผ๊ฐ€ 48์‹œ๊ฐ„์„ ์ฑ„ ๋ชป ๊ฐ€๊ธฐ ๋•Œ๋ฌธ์—, ์ž ์‹œ ์ฆ์ƒ์„ ๊ฐœ์„ ํ•˜๋Š” ์šฉ๋„ ์™ธ์—๋Š” .. ?
    • ๋”ฐ๋ผ์„œ RBC๋Š” ์ถฉ๋ถ„ํ•œ๋ฐ ํ˜ˆ์†ŒํŒ๋งŒ ์ ์€ ๊ฒฝ์šฐ์—๋Š” ๊ถŒ์žฅ๋˜์ง€ ์•Š๋Š”๋‹ค. (ex. ITP ๊ทน์ดˆ๊ธฐ)
Gastric protectants (์œ„์žฅ๊ด€๋ณดํ˜ธ์ œ)
  • Steroid ๋˜๋Š” ๋‹ค๋ฅธ ์•ฝ๋ฌผ ํˆฌ์—ฌ ํ›„ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋Š” ์†Œํ™”๊ธฐ ๋ถ€์ž‘์šฉ(GI damage) ๋ฐฉ์ง€,
  • ํ˜น์€ ์งˆ๋ณ‘ ์ž์ฒด์ ์œผ๋กœ ๋‚˜ํƒ€๋‚˜๋Š” ์œ„์žฅ๊ด€ ์ถœํ˜ˆ ์น˜๋ฃŒ.
  • H2 blocker (famotidine) / protone pump inhibitors (omeprazole) / ์œ„์‚ฐ ์–ต์ œ์ œ (sucralfate)
  • Desmopressin : vasopressin ๋Œ€์ฒด ์šฉ๋„๋กœ ์ง€ํ˜ˆ ๊ธฐ๋Šฅ์„ ๋•๊ธฐ ์œ„ํ•ด ์‚ฌ์šฉ๋˜์—ˆ์œผ๋‚˜, ํ˜„์žฌ๋Š” ๊ฑฐ์˜ ์“ฐ์ง€ ์•Š์Œ.
Evans syndrome (IMHA+ITP) : ํ•ญ์ฒด์— ์˜ํ•ด RBC๋„ ํŒŒ๊ดด, Platelet๋„ ํŒŒ๊ดด
  • ์›๋ฐœ์ธ์ง€ ์†๋ฐœ์ธ์ง€ ํ™•์ธ ํ•„์š”
  • ์˜ˆํ›„๊ฐ€ ๋ถˆ๋Ÿ‰ํ•œ ํŽธ์ด๋ผ ๊ณต๊ฒฉ์ ์ธ ์น˜๋ฃŒ๊ฐ€ ์š”๊ตฌ๋จ.
  • ์น˜๋ฃŒ guide
      1. Glucocorticoids + adjunctive immunosuppressive
      1. ์‹ฌ๊ฐํ•œ ๊ฒฝ์šฐ (platelet<15,000/ฮผL) Vincristine 1ํšŒ ์ฒ˜๋ฐฉ
      1. Trasfusion : RBC&ํ˜ˆ์†ŒํŒ ๋‘˜ ๋‹ค ํŒŒ๊ดด โ†’ ์ „ํ˜ˆ(fresh whole blood) ์ˆ˜ํ˜ˆ์ด ์ข€ ๋” ์šฉ์ดํ•จ.
      1. Heparin ์น˜๋ฃŒ ๊ธˆ์ง€โ›” : IMHA์—์„œ ํ˜ˆ์ „์ƒ‰์ „์ฆ ๋ฐฉ์ง€๋กœ ์‚ฌ์šฉ๋˜๋‚˜, ํ•ญ์‘๊ณ ์ œ ์ฒ˜๋ฐฉ์€ activeํ•œ ์ถœํ˜ˆ์ด ์žˆ์„ ๋•Œ ๋”์šฑ ์กฐ์‹ฌ; ํ˜ˆ์†ŒํŒ ๊ฐ์†Œ ์ƒํ™ฉ์—์„œ ์‹ฌํ•œ ์ถœํ˜ˆ์„ ์œ ๋ฐœํ•  ์ˆ˜ ์žˆ์Œ.

Prognosis

  • ์•„์ฃผ ๋‚˜์œ ํŽธ์€ ์•„๋‹˜, ๋ณดํ†ต. (Good to guarded)
  • ๋‹จ๊ธฐ ์ƒ์กด๋ฅ ์€ ์ข‹์€ ํŽธ์ด๋‚˜, ์งง๊ฒŒ ์‚ด์•„๋‚จ๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค. (short-term survival 74-93%)
  • ์•ฝ๋ฌผ ์น˜๋ฃŒ์— ๋ฐ˜์‘์ด ์ข‹์œผ๋‚˜, ์žฌ๋ฐœ๋ฅ ์ด ๋†’์€ ํŽธ (9-58%)
    • ์•ฝ๋ฌผ ์šฉ๋Ÿ‰ ์ค„์ด๋Š” ๊ณผ์ •์—์„œ ์žฌ๋ฐœํ•˜๋Š” ๊ฒƒ๋„ ํ”ํ•˜๋‹ค.
  • ๋ณ‘๋ฐœ ์‹œ ์˜ˆํ›„ ๋” ์•ˆ ์ข‹์Œ.
    • Megakaryocytic hypoplasia์™€ ๋ณ‘๋ฐœํ•  ๋•Œ
    • IMHA ์™€ ๋ณ‘๋ฐœํ•  ๋•Œ (Evans syndrome) : IMHA ๋‹จ๋…๋ณด๋‹ค ์˜ˆํ›„ ์•ˆ ์ข‹๋‹ค๋Š” ๊ทผ๊ฑฐ๋Š” ๋ถ€์กฑ.